Meet The Team

Andrew Winkley

PhD, DABT

Andrew has over 20 years of drug safety experience in industry at AstraZeneca and Vertex. He has a broad scientific background that includes mechanistic and regulatory toxicology, and biochemistry. His drug development experience covers the complete life cycle of drug development from discovery to late-stage development in several therapeutic areas including orphan indications, neuroscience, pain therapeutics, inflammatory diseases, infectious diseases, and oncology. Andrew has been involved in bringing several candidate molecules to clinical trials and most recently completed an NDA/MAA for a cystic fibrosis drug. Andrew is a highly adaptive project toxicologist who can assimilate and interpret a broad range of data from various disciplines to provide clear guidance to the project team.